Results 201 to 210 of about 146,093 (222)
Some of the next articles are maybe not open access.
[Angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor blockers].
Nihon rinsho. Japanese journal of clinical medicine, 2007Masaki, Mogi, Masatsugu, Horiuchi
openaire +1 more source
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Ca-A Cancer Journal for Clinicians, 2020Vaibhav G Patel +2 more
exaly
Breast cancer statistics, 2019
Ca-A Cancer Journal for Clinicians, 2019Carol E Desantis, Jiemin, Mia M Gaudet
exaly
Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
Journal of human hypertension, 1997Candesartan is a potent and selective angiotensin II type 1 receptor blocker which binds tightly to and dissociates slowly from the AT1 receptor. It is administered orally as the prodrug candesartan cilexetil, which is rapidly and completely converted to the active compound, candesartan, during gastrointestinal absorption.
openaire +1 more source
An overview of precision oncology basket and umbrella trials for clinicians
Ca-A Cancer Journal for Clinicians, 2020Kristian Thorlund, Edward J Mills
exaly
Breast cancer statistics, 2017, racial disparity in mortality by state
Ca-A Cancer Journal for Clinicians, 2017Carol E Desantis +2 more
exaly
Evolving standards of care and new challenges in the management of HER2‐positive breast cancer
Ca-A Cancer Journal for Clinicians, 2020Grace M Choong +2 more
exaly